Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Semaphorin 4 in multiple sclerosis].
Therapeutic Potential of the Modulation of Sphingosine 1 phosphate receptors.
Seronegative neuromyelitis optica after cardiac transplantation.
Multiple sclerosis and pregnancy: a comparison study.
Association analysis of nitric oxide synthases: NOS1, NOS2A and NOS3 genes, with multiple sclerosis.
Association between multiple sclerosis risk-associated SNPs and relapse and disability - a prospective cohort study.
Clinical Manifestations and Spinal Cord Magnetic Resonance Imaging Findings in Chinese Neuromyelitis Optica Patients.
Evaluation of the humoral response against mycobacterial peptides, homologous to MOG35-55, in multiple sclerosis patients.
Myelinating cocultures of rat retinal ganglion cell reaggregates and optic nerve oligodendrocyte precursor cells.
Aquaporin-1 Antibody in Neuromyelitis Optica Patients.
Tablet-based screening improves continence management in multiple sclerosis.
Correction: Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
Laquinimod, an upcoming oral immunomodulatory agent for treatment of multiple sclerosis.
Gut commensalism, cytokines, and central nervous system demyelination.
Advances in myelin imaging with potential clinical application to pediatric imaging.
Early magnetic resonance detection of natalizumab-related progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
Comparing neuromyelitis optica and multiple sclerosis severity: is there a difference?
Blinded and unblinded internal pilot study designs for clinical trials with count data.
Interpretation of magnetization transfer from inhomogeneously broadened lines (ihMT) in tissues as a dipolar order effect within motion restricted molecules.
Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments.
Active Cognitive Reserve Influences the Regional Atrophy to Cognition Link in Multiple Sclerosis.
BCG vaccine for clinically isolated syndrome and MS: Infections and protective immunity.
Remote Neurodegeneration: Multiple Actors for One Play.
Clinical outcome measures in multiple sclerosis.
Pages
« first
‹ previous
…
649
650
651
652
653
654
655
656
657
…
next ›
last »